Celera has entered into a research collaboration with Merck to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate certain gene expression profiles identified by Merck with the goal of developing diagnostic predictors for use in Merck’s clinical trials, and to potentially form the basis for commercial diagnostic tests for oncology therapies. Celera will receive an undisclosed payment for this collaboration and is elig...